AU2002221939A1 - Rapidly disintegrating tablet comprising an acid-labile active ingredient - Google Patents

Rapidly disintegrating tablet comprising an acid-labile active ingredient

Info

Publication number
AU2002221939A1
AU2002221939A1 AU2002221939A AU2193902A AU2002221939A1 AU 2002221939 A1 AU2002221939 A1 AU 2002221939A1 AU 2002221939 A AU2002221939 A AU 2002221939A AU 2193902 A AU2193902 A AU 2193902A AU 2002221939 A1 AU2002221939 A1 AU 2002221939A1
Authority
AU
Australia
Prior art keywords
active ingredient
acid
rapidly disintegrating
disintegrating tablet
labile active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002221939A
Inventor
Rango Dietrich
Rudolf Linder
Hartmut Ney
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda GmbH
Original Assignee
Byk Gulden Lomberg Chemische Fabrik GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Byk Gulden Lomberg Chemische Fabrik GmbH filed Critical Byk Gulden Lomberg Chemische Fabrik GmbH
Publication of AU2002221939A1 publication Critical patent/AU2002221939A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Food Preservation Except Freezing, Refrigeration, And Drying (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A rapidly disintegrating tablet for oral administration of acid-labile active ingredients is described. The rapidly disintegrating tablet for oral administration of an acid-labile active ingredient comprises a plurality of individual active ingredient units together with pharmaceutical excipients, where the acid-labile active ingredient is present in the individual active ingredient units in a matrix composed of a mixture comprising at least one solid paraffin and one or more substances from the group of fatty alcohol, triglyceride and fatty acid ester, and where excipients which, on oral intake of the tablet, bring about rapid disintegration of the tablet are present.
AU2002221939A 2000-12-07 2001-12-06 Rapidly disintegrating tablet comprising an acid-labile active ingredient Abandoned AU2002221939A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00126807 2000-12-07
EP00126807 2000-12-07
PCT/EP2001/014340 WO2002045694A1 (en) 2000-12-07 2001-12-06 Rapidly disintegrating tablet comprising an acid-labile active ingredient

Publications (1)

Publication Number Publication Date
AU2002221939A1 true AU2002221939A1 (en) 2002-06-18

Family

ID=8170591

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002221939A Abandoned AU2002221939A1 (en) 2000-12-07 2001-12-06 Rapidly disintegrating tablet comprising an acid-labile active ingredient

Country Status (16)

Country Link
US (1) US7147869B2 (en)
EP (1) EP1341528B1 (en)
JP (1) JP2004514737A (en)
KR (1) KR20030072555A (en)
CN (1) CN100335040C (en)
AT (1) ATE541564T1 (en)
AU (1) AU2002221939A1 (en)
BR (1) BR0115986A (en)
CA (1) CA2430829C (en)
CY (1) CY1112615T1 (en)
DK (1) DK1341528T3 (en)
ES (1) ES2380654T3 (en)
HK (1) HK1062264A1 (en)
PT (1) PT1341528E (en)
SI (1) SI1341528T1 (en)
WO (1) WO2002045694A1 (en)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7988999B2 (en) * 2000-12-07 2011-08-02 Nycomed Gmbh Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient
AU2002234545A1 (en) * 2000-12-07 2002-06-18 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Pharmaceutical preparation in the form of a suspension comprising an acid-labileactive ingredient
UA80393C2 (en) * 2000-12-07 2007-09-25 Алтана Фарма Аг Pharmaceutical preparation comprising an pde inhibitor dispersed on a matrix
RU2301662C2 (en) * 2001-07-16 2007-06-27 Астразенека Аб Pharmaceutical preparation containing proton pump inhibitor and antacids
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
EP1606261B1 (en) 2003-03-10 2009-11-04 Nycomed GmbH Novel process for the preparation of roflumilast
CL2004000983A1 (en) 2003-05-08 2005-03-04 Altana Pharma Ag ORAL PHARMACEUTICAL COMPOSITION IN THE FORM OF A TABLET THAT INCLUDES DIHYDRATED MAGNETIC PANTOPRAZOL, WHERE THE TABLET FORM IS COMPOSED BY A NUCLEUS, A MIDDLE COAT AND AN OUTER LAYER; AND USE OF PHARMACEUTICAL COMPOSITION IN ULCERAS AND
PE20050150A1 (en) 2003-05-08 2005-03-22 Altana Pharma Ag A DOSAGE FORM CONTAINING (S) -PANTOPRAZOLE AS AN ACTIVE INGREDIENT
JP5563735B2 (en) * 2004-06-16 2014-07-30 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド PPI multiple dosage form
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US8057820B2 (en) * 2004-10-08 2011-11-15 Mcneil-Ppc, Inc. Enteric coated aspirin granules comingled with binder
US8758814B2 (en) * 2004-10-08 2014-06-24 Mcneil-Ppc, Inc. Chewable enteric coated aspirin tablets
CA2601250C (en) 2005-03-16 2014-10-28 Nycomed Gmbh Taste masked dosage form containing roflumilast
FR2885526B1 (en) * 2005-05-13 2007-07-27 Flamel Technologies Sa ORAL MEDICINE BASED ON PROTON PUMP INHIBITOR
CN100431526C (en) * 2005-11-07 2008-11-12 上海艾力斯医药科技有限公司 A rapidly disintegrating tablet of acid sensitive drug
US8497258B2 (en) 2005-11-12 2013-07-30 The Regents Of The University Of California Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
JP5209492B2 (en) * 2005-12-21 2013-06-12 ビーエーエスエフ ソシエタス・ヨーロピア Pharmaceutical formulations for the production of fast-disintegrating tablets
US8568780B2 (en) * 2007-06-06 2013-10-29 Basf Se Pharmaceutical formulation for the production of rapidly disintegrating tablets
BRPI0812064B8 (en) * 2007-06-06 2021-05-25 Basf Se pharmaceutical formulation in the form of pellets, tablets, and, process for the production of a pharmaceutical formulation
CN104069088A (en) * 2007-10-12 2014-10-01 武田制药北美公司 Methods of treating gastrointestinal disorders independent of the intake of food
DE102010011421A1 (en) * 2009-03-19 2010-09-30 Schaeffler Technologies Gmbh & Co. Kg Switchable drag lever of a valve train of an internal combustion engine
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
WO2010144865A2 (en) 2009-06-12 2010-12-16 Meritage Pharma, Inc. Methods for treating gastrointestinal disorders
US20130052278A1 (en) * 2010-03-11 2013-02-28 Rich Vitamins Llc Quick dissolve nutritional powder
EP2441445A1 (en) * 2010-10-14 2012-04-18 Deva Holding Anonim Sirketi Coating of cetyl myristate and/or cetyl palmitate particles
EP2441446A1 (en) * 2010-10-14 2012-04-18 Deva Holding Anonim Sirketi Using of superdisintegrants in cetyl myristate and/or cetyl palmitate formulations
JP5913367B2 (en) 2011-01-05 2016-04-27 ホスピーラ インコーポレイテッド Spray drying vancomycin
CN104043104B (en) 2013-03-15 2018-07-10 浙江创新生物有限公司 The spray dried powder and its industrialized process for preparing of hydrochloric vancomycin
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065142A (en) * 1958-07-30 1962-11-20 Armour Pharma Gastric resistant medicinal preparation
US4006227A (en) * 1973-11-15 1977-02-01 Gallegos Alfred J Compositions and methods for fertility control
SE7804231L (en) 1978-04-14 1979-10-15 Haessle Ab Gastric acid secretion
JPS6150978A (en) 1984-08-16 1986-03-13 Takeda Chem Ind Ltd Pyridine derivative and preparation thereof
GB2189699A (en) 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
FI90544C (en) 1986-11-13 1994-02-25 Eisai Co Ltd Process for Preparation as Drug Useful 2-Pyridin-2-yl-methylthio- and sulfinyl-1H-benzimidazole derivatives
US5380535A (en) * 1991-05-28 1995-01-10 Geyer; Robert P. Chewable drug-delivery compositions and methods for preparing the same
ATE245023T1 (en) * 1991-05-28 2003-08-15 Mcneil Ppc Inc CHEWABLE DRUG RELEASE COMPOSITION
PH31467A (en) * 1994-01-31 1998-11-03 Yamanouchi Pharma Co Ltd Intrabucally dissolving compressed mouldings and production process thereof.
SE9402431D0 (en) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
DE29522419U1 (en) 1994-07-08 2003-07-03 AstraZeneca AB, Södertälje Multiple unit tabletted dosage form contg omeprazole - comprising enteric coated layered units of core material contg omeprazole compressed with excipients into tablets
SE512835C2 (en) 1996-01-08 2000-05-22 Astrazeneca Ab Dosage form containing a plurality of units all containing acid labile H + K + ATPase inhibitors
JP4939680B2 (en) * 1997-05-27 2012-05-30 武田薬品工業株式会社 Solid preparation
CN100379407C (en) * 1997-12-19 2008-04-09 史密丝克莱恩比彻姆公司 Process for manufacturing bite-dispersion tablets
SE9704869D0 (en) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
DK1121103T3 (en) * 1998-05-18 2007-04-30 Takeda Pharmaceutical Orally disintegrable tablets comprising a benzimidazole
DK1100469T3 (en) * 1998-07-28 2005-04-18 Takeda Pharmaceutical Fast decaying solid preparation
SE9803240D0 (en) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
DE19925710C2 (en) * 1999-06-07 2002-10-10 Byk Gulden Lomberg Chem Fab New preparation and dosage form containing an acid labile proton pump inhibitor
CA2376202C (en) * 1999-06-07 2008-11-18 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel preparation and administration form comprising an acid-labile active compound

Also Published As

Publication number Publication date
HK1062264A1 (en) 2004-10-29
CA2430829C (en) 2010-06-22
CY1112615T1 (en) 2016-02-10
ES2380654T3 (en) 2012-05-17
CA2430829A1 (en) 2002-06-13
WO2002045694A1 (en) 2002-06-13
ATE541564T1 (en) 2012-02-15
CN100335040C (en) 2007-09-05
JP2004514737A (en) 2004-05-20
BR0115986A (en) 2003-12-23
SI1341528T1 (en) 2012-05-31
EP1341528A1 (en) 2003-09-10
US7147869B2 (en) 2006-12-12
PT1341528E (en) 2012-03-20
US20040110661A1 (en) 2004-06-10
DK1341528T3 (en) 2012-03-26
CN1479613A (en) 2004-03-03
EP1341528B1 (en) 2012-01-18
KR20030072555A (en) 2003-09-15

Similar Documents

Publication Publication Date Title
AU2002221939A1 (en) Rapidly disintegrating tablet comprising an acid-labile active ingredient
AU1607302A (en) Pharmaceutical preparation comprising an active dispersed on a matrix
HUP0000976A2 (en) Multiple unit effervescent tablet dosage forms comprising protonpump inhibitor
AP2397A (en) Matrix for sustained, invariant and independent release of active compounds.
HUP0201637A2 (en) Novel preparation and administration form comprising an acid-labile active compound
ATE334689T1 (en) ADMINISTRATION MEDIUM FOR ANALGESIC, ANTI-INFLAMMATORY AND ANTIPYRETIC ACTIVE INGREDIENTS AND PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH MEDIUM AND ACTIVE INGREDIENTS
BG102228A (en) Medicamentous form with controlled release of slightly soluble medicamentous substances
AR032073A1 (en) THE ANPHIFILIC LIPID NANOPARTICLES FOR THE INCORPORATION OF PEPTIDES AND / OR PROTEINS
EP1275381A4 (en) Time-release coated solid compositions for oral administration
CA2430816A1 (en) Pharmaceutical preparation in the form of a paste comprising an acid-labile active ingredient
UA42062C2 (en) Three-phase pharmaceutical form with constant and sustained release of amorphous active ingredient and methods for its manufacture
WO1998058629A3 (en) Preparation of pharmaceutical compositions
SE9704401D0 (en) Matrix pellets for greasy, oily or sticky drug substances
TWI255720B (en) Novel preparation and administration form comprising an acid-labile active compound and process for production thereof
CA2430824A1 (en) Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient
RS50298B (en) Directly compressibile matrix for controlled release of single daily doses of clarithromycin
CA2473718A1 (en) Immediate-release pharmaceutical dosage form comprising polymorphous tibolone
UA77246C2 (en) Pharmaceutical composition containing pancreatin and dry extract from herb of pea